Publication details
Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells
| Authors | |
|---|---|
| Year of publication | 2020 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy |
| Related projects: |